FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100072109> ?p ?o ?g. }

• W2100072109 endingPage "1411" @default.
• W2100072109 startingPage "1406" @default.
• W2100072109 abstract "An increased incidence of de novo malignancies in immunocompromised patients was first predicted by Professor Thomas Starzl and coworkers in 1968 and was confirmed shortly afterwards by others.1-4 The immunocompromised state provides a permissive environment for malignant cells to grow, for an oncogenic virus to infect or reactivate within the host, for chronic antigen stimulation leading to a cytokine-rich milieu, and for impaired immune surveillance imposed by chronic immunosuppression.5-7 With the increasing success of liver transplantation (LTx) and fewer episodes of acute rejection with virtual freedom from chronic rejection, long-term survival rates have improved.8-11 In addition, with an aging population, older recipients are also being considered for LTx.12 Currently, long-term graft loss and death are not commonly related to rejection but are often due to age-related complications, such as cardiovascular disease and de novo cancers.13, 14 The rate of de novo cancers after LTx has been reported to range from 3% to 26%,15-18 and the variation is partly due to the length of follow-up, different ways of reporting, and geographic variations in de novo malignancies. Although registry data of de novo cancers provide a valuable source for accounting for the various types of malignancies; these registries do not include the denominator of the population at risk. The cumulative number of years of follow-up is also unknown, and this makes it difficult to calculate the actuarial risk.2, 6, 19-21 In this respect, data from single centers with long-term follow-up have become an important source of information for the incidence and nature of de novo cancers, which can then be compared with surveillance epidemiological end results data. Furthermore, these data can be presented as a standard incident ratio (SIR). Also, the incidence of de novo cancers can be evaluated on the basis of the number of person years post-transplantation; the cumulative actual survival of patients after transplants is included until the last follow-up or time of death. Within the published literature, there are significant inconsistencies in the reporting of de novo malignancies. For example, some authors prefer to include posttransplant lymphoproliferative disorders (PTLDs) along with de novo solid cancers,22-30 whereas others prefer not to include them.15, 18, 31, 32 This has caused a major discrepancy in reported rates of de novo cancers. Non-melanoma, non-Kaposi's skin cancers (squamous cell cancer and basal cell carcinoma) are the commonest types of de novo malignancies in the posttransplant population, with an up to 70 times higher incidence in comparison with nontransplant populations.24, 30, 33-35 One way to report this is to separate lymphoid lesions from nonlymphoid cancers and then separate the nonlymphoid cancers. Even after stratification of lymphoid and nonlymphoid cancers in this manner, there appears to be a wide variation in the different types of de novo cancers. In the report by Åberg and coworkers36 in this issue of Liver Transplantation, squamous cell carcinoma, melanoma, and Kaposi's sarcoma are included, whereas basal cell carcinoma of the skin is mentioned but is omitted from the calculation of the incidence and SIR. Lymphoid malignancies are also included in the current report. They show that the cumulative incidence of de novo cancers increased at 1, 5, 10, and 20 years of follow-up to 3%, 5%, 13%, and 16%, respectively. This can be compared to Haagsma et al.'s report,24 which showed a cumulative risk of de novo malignancies (lymphoid cancers included) of 6%, 20%, and 55% at 5, 10, and 15 years post-LTx, respectively. The study population of 1000 consecutive post-LTx patients using tacrolimus from the University of Pittsburgh was first examined in August 1999 for de novo cancers with a mean follow-up of 77.8 ± 11.1 months (4795.3 total person years).32 There were 57 cases of de novo cancers in all (lymphoid lesions excluded), which included 22 nonmelanoma, non-Kaposi's skin cancers. This incidence increased when the longitudinal follow-up was extended to 8199 person years in December 2002.14 At that time point, there were 87 cases of de novo nonlymphoid malignancies (10.62 cases per 100 person years of follow-up). They consisted of 33 nonmelanoma, non-Kaposi's skin cancers and 54 other malignancies (Table 1). The details of the various de novo cancers are shown in (Table 2). IBD, inflammatory bowel disease; LTx, liver transplantation; PSC, primary sclerosing cholangitis; PTLD, posttransplant lymphoproliferative disorder; SIR, standard incident ratio. Of interest was the variation in the incidence and nature of de novo malignancies in different age populations in this group. Herrero et al.16 reviewed 187 cases and found 63 malignancies (lymphoid lesions included). On a univariate analysis, for they found age to be a significant risk factor for de novo cancers (P = 0.01). Similarly, Haagsma et al.24 found age > 40 years to be a significant risk factor for an increase in de novo cancer compared to age < 40 years (P = 0.006; lymphoid lesions included).24 In the University of Pittsburgh population, the numbers of nonlymphoid de novo malignancies in the age groups of ≤40 years (n = 354), >40 to ≤60 years (n = 442), and >60 years (n = 204) were 7 (1.97%), 47 (10.63%), and 33 (16.17%), respectively (Table 2). When expressed in terms of incidence per 100 person years post-LTx, the rates were 2.11, 13.46, and 23.91 in the age groups of ≤40 years, >40 to ≤60 years, and >60 years, respectively. The distribution of the de novo nonmelanoma, non-Kaposi's skin cancers and other malignancies is also given in relation to 100 person years for different age groups in Table 1 and Fig. 1. De novo cancers per 100 person years post–liver transplantation in various age groups. As pointed out by the University of Pittsburgh, there is an inverse relationship to the rate of PTLD with de novo cancers with respect to the age at transplant.13 The rate of PTLD was examined in the same 1000-patient population for the same duration of follow-up used for de novo cancers: overall, 43 cases were identified. The rates of PTLD in the age groups of ≤18 years (n = 166), >18 to ≤40 years (n = 188), >40 to ≤ 60 years (n = 442), and >60 years (n = 204) were 10.8%, 2.7%, 3.2%, and 2.9% respectively (Table 3). In the previously reported study from the University of Pittsburgh of PTLD in 4000 patients who were followed for nearly 20 years, the rate of PTLD decreased with time, and the children had a higher incidence than the adults.37 Skin cancers are the most common types of de novo cancers in all the reported series, with an up to 70 times higher increase in the incidence in comparison with nontransplant populations.29, 30, 33-35 The incidence is extremely high in the Australian reports and is lowest in the Japanese studies.34 The overall incidence reported from various studies ranges from 30% to 70% for all tumors after LTx.24, 38, 39 There is an increased incidence of oropharyngeal and lung cancers in tobacco users. In the United States, 20% to 25% of liver transplants are performed for patients with alcohol-related end-stage liver disease, a majority of whom are also tobacco users.12, 40 In 1 study, more than 50% of patients transplanted for alcohol-related diseases had a history of smoking.41 DiMartini and coworkers42 from the University of Pittsburgh reported a prospective study confirming the underreporting of smoking. An epidemiological study of 1.2 million US adults with alcohol consumption revealed a significantly higher risk for oral, esophageal, pharyngeal, laryngeal, and liver cancers in middle-aged and elderly populations.43 In our study, the incidence of oropharyngeal cancers was 25.5 times higher and the incidence of lung cancer was 3.7 times higher for alcohol-related end-stage liver disease patients. A higher incidence of lung cancer post-LTx with poorer prognosis has been reported by Jiménez et al.44 and others.41, 42, 45 In contrast, Haagsma and others did not find any cases of oropharyngeal cancer in their series,20, 24, 27, 46-48 and only 1 case of oropharyngeal and lung cancer was observed in the present study by Åberg and coworkers,36 which included 54 cases of alcoholic cirrhosis. An increased incidence of de novo esophageal cancers has been reported in patients with Barrett's esophagitis.49 Careful follow-up with gastrointestinal endoscopy may provide a survival benefit in such cases.50 Nagata and coworkers51 reported a single case of gastric cancer post-LTx in which a Helicobacter pylori infection was noted. Adami et al.33 reported a 2-fold increase in the risk for gastric cancer and a 3-fold increase in the risk for esophageal cancer. Yao et al.17 reported a high proportion of gastrointestinal tumors (46% of all nonskin, nonlymphoid cancers) in a case control study with a high incidence of small bowel malignancies. Vera and associates52 (Birmingham, United Kingdom) found a 5.3% incidence of colonic cancers in patients with primary sclerosing cholangitis (PSC) versus 0.6% for non-PSC patients. However, although Loftus et al.53 found a 4-fold increase in colon cancer in their posttransplant population, this rate was not significantly higher when it was compared to the rate in other patients with inflammatory bowel disease (IBD). In a study comparing the risk of colon cancers in patients with LTx and a history of IBD, Bleday et al.54 found early colorectal neoplasms in 11.1% of cases with surveillance colonoscopy The most common genitourinary malignancy is prostate cancer. However, the incidence does not appear to be higher in the post-LTx population.17, 18, 22, 23, 26, 32, 33 Haagsma and coworkers24 from the Netherlands reported a 30-fold increase in de novo cancers of the kidney. Also, in a large Swedish post–kidney and liver transplant population study of 5931 cases, SIR for kidney cancer was 4.9 times higher.24, 33 The Israel Penn registry of kidney transplant recipients3 and Adami et al.33 in a study of kidney and liver transplant recipients have reported an increased incidence of vulval and cervical cancers after transplantation. Jonas et al.26 reported a high incidence of cervical intraepithelial neoplasia in patients post-LTx using quadruple therapy. De novo breast cancers post-LTx were summarized by Oruc et al.55 (University of Pittsburgh). Most of them were diagnosed in the early stages, and the overall survival was similar to that of nontransplant recipients.29 A synergistic effect between alcohol use and estrogen on the risk of breast cancer has also been suggested.56 In conclusion, there is a wide variation in the incidence of post-LTx de novo cancers, which is partly related to the length of follow-up and partly related to the inclusion or exclusion of lymphoid lesions. There is also a wide variation in reported cancer types by geographic distribution. Oropharyngeal cancers are more commonly seen in those with alcoholic liver disease and particularly in those with a smoking history. The rate of renal cell cancers was much higher in the series of cases from the Netherlands. Colonic cancers are more common in patients with PSC and IBD. Barrett's esophagitis is a risk for carcinoma esophagus. The overall rate of de novo solid tumors increases with age at the time of transplant and the length of follow-up, whereas the rate of PTLD decreases with age at LTx, with a higher incidence in the first few years post-LTx." @default.
• W2100072109 created "2016-06-24" @default.
• W2100072109 creator A5003838699 @default.
• W2100072109 creator A5007117355 @default.
• W2100072109 creator A5054972548 @default.
• W2100072109 date "2008-09-29" @default.
• W2100072109 modified "2023-10-16" @default.
• W2100072109 title "Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up" @default.
• W2100072109 cites W1608051388 @default.
• W2100072109 cites W1969333586 @default.
• W2100072109 cites W1985702786 @default.
• W2100072109 cites W1992284814 @default.
• W2100072109 cites W1993763408 @default.
• W2100072109 cites W1996883206 @default.
• W2100072109 cites W2013962519 @default.
• W2100072109 cites W2014896408 @default.
• W2100072109 cites W2020329640 @default.
• W2100072109 cites W2021089495 @default.
• W2100072109 cites W2021905006 @default.
• W2100072109 cites W2022112812 @default.
• W2100072109 cites W2027008491 @default.
• W2100072109 cites W2027286769 @default.
• W2100072109 cites W2036108790 @default.
• W2100072109 cites W2036878352 @default.
• W2100072109 cites W2041457021 @default.
• W2100072109 cites W2043276581 @default.
• W2100072109 cites W2045699302 @default.
• W2100072109 cites W2049798004 @default.
• W2100072109 cites W2050485376 @default.
• W2100072109 cites W2052095993 @default.
• W2100072109 cites W2052868106 @default.
• W2100072109 cites W2053758773 @default.
• W2100072109 cites W2065754270 @default.
• W2100072109 cites W2066157289 @default.
• W2100072109 cites W2074261174 @default.
• W2100072109 cites W2082112921 @default.
• W2100072109 cites W2084653699 @default.
• W2100072109 cites W2085582137 @default.
• W2100072109 cites W2107129971 @default.
• W2100072109 cites W2109810752 @default.
• W2100072109 cites W2116437061 @default.
• W2100072109 cites W2125778084 @default.
• W2100072109 cites W2128445213 @default.
• W2100072109 cites W2133408276 @default.
• W2100072109 cites W2133676969 @default.
• W2100072109 cites W2146527085 @default.
• W2100072109 cites W2147432994 @default.
• W2100072109 cites W2153139689 @default.
• W2100072109 cites W2153497877 @default.
• W2100072109 cites W2157836255 @default.
• W2100072109 cites W2159254384 @default.
• W2100072109 cites W2335592377 @default.
• W2100072109 cites W2410600946 @default.
• W2100072109 cites W4229520794 @default.
• W2100072109 cites W4230154854 @default.
• W2100072109 doi "https://doi.org/10.1002/lt.21609" @default.
• W2100072109 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18825680" @default.
• W2100072109 hasPublicationYear "2008" @default.
• W2100072109 type Work @default.
• W2100072109 sameAs 2100072109 @default.
• W2100072109 citedByCount "28" @default.
• W2100072109 countsByYear W21000721092012 @default.
• W2100072109 countsByYear W21000721092013 @default.
• W2100072109 countsByYear W21000721092014 @default.
• W2100072109 countsByYear W21000721092015 @default.
• W2100072109 countsByYear W21000721092016 @default.
• W2100072109 countsByYear W21000721092017 @default.
• W2100072109 countsByYear W21000721092019 @default.
• W2100072109 countsByYear W21000721092020 @default.
• W2100072109 countsByYear W21000721092022 @default.
• W2100072109 crossrefType "journal-article" @default.
• W2100072109 hasAuthorship W2100072109A5003838699 @default.
• W2100072109 hasAuthorship W2100072109A5007117355 @default.
• W2100072109 hasAuthorship W2100072109A5054972548 @default.
• W2100072109 hasConcept C112758219 @default.
• W2100072109 hasConcept C120665830 @default.
• W2100072109 hasConcept C121332964 @default.
• W2100072109 hasConcept C121608353 @default.
• W2100072109 hasConcept C124952713 @default.
• W2100072109 hasConcept C126322002 @default.
• W2100072109 hasConcept C142362112 @default.
• W2100072109 hasConcept C143998085 @default.
• W2100072109 hasConcept C2776231280 @default.
• W2100072109 hasConcept C2776995267 @default.
• W2100072109 hasConcept C2779338263 @default.
• W2100072109 hasConcept C2779609443 @default.
• W2100072109 hasConcept C2911091166 @default.
• W2100072109 hasConcept C61511704 @default.
• W2100072109 hasConcept C71924100 @default.
• W2100072109 hasConceptScore W2100072109C112758219 @default.
• W2100072109 hasConceptScore W2100072109C120665830 @default.
• W2100072109 hasConceptScore W2100072109C121332964 @default.
• W2100072109 hasConceptScore W2100072109C121608353 @default.
• W2100072109 hasConceptScore W2100072109C124952713 @default.
• W2100072109 hasConceptScore W2100072109C126322002 @default.
• W2100072109 hasConceptScore W2100072109C142362112 @default.
• W2100072109 hasConceptScore W2100072109C143998085 @default.
• W2100072109 hasConceptScore W2100072109C2776231280 @default.

• next